🇪🇺 Rimegepant for acute migraine treatment in European Union

Rimegepant for acute migraine treatment (rimegepant-for-acute-migraine-treatment) regulatory status in European Union.

Marketing authorisation

EMA

  • Status: approved

Rimegepant for acute migraine treatment in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is Rimegepant for acute migraine treatment approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Rimegepant for acute migraine treatment in European Union?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.